Sector News

Ansell to buy UK-based protective clothing maker Microgard

April 1, 2015
Life sciences
Glove and condom maker Ansell Limited will acquire UK-based protective clothing manufacturer Microgard for £59 million ($A113m).
 
Microgard has sales in more than 75 countries, a manufacturing facility in Xiamen, China and about 750 employees worldwide.
 
The company has grown rapidly, mainly in Europe, the Middle East and Africa, and in the Asia-Pacific region, with sales of about $US40m during calendar year 2014, Ansell said in a statement today.
 
Ansell (ANN) chief executive Magnus Nicolin said the acquisition was a critical step in building the company’s body protection operations, as part of its Industrial Global Business unit.
 
“Together with our current chemical protective glove range, we now have a world-class portfolio of chemical protection solutions, leveraging our strong global footprint,” he said.
 
Microgard supplies customers in the industrial, chemical, oil and gas and life science sectors and Mr Nicolin said the purchase would complement previous acquisitions that had expanded Ansell’s product range.
 
Ansell expects the acquisition, including all transaction costs, to be marginally dilutive to earnings per share in fiscal 2015 and to be accretive in fiscal 2016.
 
The purchase price is equivalent to a multiple of about nine times on trailing 12-months adjusted earnings before interest, tax, depreciation and amortisation, according to the company.
 
The deal is subject to German antitrust clearance and is expected to complete during the second quarter of the current calendar year.
 

comments closed

Related News

May 17, 2024

With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide

Life sciences

Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.

May 17, 2024

Sanofi invests €1 Billion to boost drug manufacturing in France

Life sciences

The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.

May 17, 2024

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Life sciences

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.

How can we help you?

We're easy to reach